The FLAURA2 Regimen: Adding Chemotherapy to Targeted Therapy in Frontline EGFR-Mutant NSCLC

This segment focuses on combining osimertinib with platinum-pemetrexed chemotherapy as a first-line intensification strategy. The faculty walk through the regimen's structure, an induction phase of doublet chemotherapy followed by maintenance, and review its improvement in progression-free survival and, on later analysis, overall survival compared with monotherapy. They discuss which patients appear to derive the most benefit, including those with central nervous system involvement and certain higher-risk mutation subtypes, while noting that older patients may see a more attenuated advantage given the added toxicity. Much of the conversation is practical: toxicity is front-loaded to the chemotherapy phase, with fatigue, gastrointestinal effects, and cytopenias that most oncologists are comfortable managing, and the majority of patients remain on their targeted therapy throughout. The panel details monitoring during induction and the shift to maintenance considerations such as renal function and cumulative fatigue, offering a real-world view of delivering this regimen well.